The phase I study assessing the safety, tolerability, and relative bioavailability of SAGE-217 Capsules

Next Previous
Trial Profile

The phase I study assessing the safety, tolerability, and relative bioavailability of SAGE-217 Capsules

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs SAGE 217 (Primary) ; SAGE 217
  • Indications Bipolar depression; Dyskinesias; Essential tremor; Insomnia; Major depressive disorder; Parkinson's disease; Postnatal depression; Seizures
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 29 Mar 2018 New trial record
    • 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top